2bcd2fcf-9050-4713-aa6b-6cb1419d7ba6
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 81
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.430
- INTERFERON_ALPHA_RESPONSE+0.420
- E2F_TARGETS+0.360
- MITOTIC_SPINDLE+0.350
- OXIDATIVE_PHOSPHORYLATION+0.350
- MYC_TARGETS_V1+0.290
- MYC_TARGETS_V2+0.240
- PROTEIN_SECRETION+0.200
- ESTROGEN_RESPONSE_LATE+0.190
- ESTROGEN_RESPONSE_EARLY+0.180
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.560
- ANGIOGENESIS-0.410
- INFLAMMATORY_RESPONSE-0.320
- COAGULATION-0.310
- HYPOXIA-0.270
- ALLOGRAFT_REJECTION-0.260
- APICAL_SURFACE-0.250
- IL2_STAT5_SIGNALING-0.170
- MYOGENESIS-0.160
- APICAL_JUNCTION-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A18L-01A-32R-A12D-07 | — | B | 0.857 |
| 2 | SRR6013515 | — | cohortA4 | 0.844 |
| 3 | SRR975555 | — | — | 0.843 |
| 4 | 04e3aeba-c9bd-483d-9484-5ecc0e64a054 | — | — | 0.834 |
| 5 | SRR15030853 | — | — | 0.811 |
| 6 | TCGA-DK-A3IS-01A-21R-A21D-07 | — | — | 0.808 |
| 7 | TCGA-44-5643-01A-01R-1628-07 | — | cohortSQ2 | 0.805 |
| 8 | MDT-AP-0447 | Med | Medulloblastoma | 0.795 |
| 9 | TCGA-A2-A0CW-01A-21R-A115-07 | — | B | 0.787 |
| 10 | TCGA-AO-A03O-01A-11R-A00Z-07 | — | C | 0.787 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.430 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.420 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.360 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.350 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.350 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.290 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.240 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.190 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.180 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.170 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.130 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.120 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.120 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.110 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.070 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.060 | Inavolisib | — uncovered |
| PEROXISOME | 0.060 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.030 | Cobimetinib | — uncovered |